Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GSK3A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GSK3A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GSK3A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GSK3A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GSK3A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GSK3A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00431612 | Colorectum | MSS | proteasome-mediated ubiquitin-dependent protein catabolic process | 127/3467 | 412/18723 | 7.70e-10 | 6.32e-08 | 127 |
GO:00194392 | Colorectum | MSS | aromatic compound catabolic process | 140/3467 | 467/18723 | 8.56e-10 | 6.85e-08 | 140 |
GO:19033202 | Colorectum | MSS | regulation of protein modification by small protein conjugation or removal | 82/3467 | 242/18723 | 7.49e-09 | 4.63e-07 | 82 |
GO:00903162 | Colorectum | MSS | positive regulation of intracellular protein transport | 60/3467 | 160/18723 | 1.18e-08 | 7.08e-07 | 60 |
GO:20000582 | Colorectum | MSS | regulation of ubiquitin-dependent protein catabolic process | 61/3467 | 164/18723 | 1.28e-08 | 7.61e-07 | 61 |
GO:00224112 | Colorectum | MSS | cellular component disassembly | 130/3467 | 443/18723 | 1.44e-08 | 8.46e-07 | 130 |
GO:00611362 | Colorectum | MSS | regulation of proteasomal protein catabolic process | 67/3467 | 187/18723 | 1.45e-08 | 8.47e-07 | 67 |
GO:00323882 | Colorectum | MSS | positive regulation of intracellular transport | 70/3467 | 202/18723 | 3.32e-08 | 1.82e-06 | 70 |
GO:00510522 | Colorectum | MSS | regulation of DNA metabolic process | 108/3467 | 359/18723 | 5.86e-08 | 3.10e-06 | 108 |
GO:19033642 | Colorectum | MSS | positive regulation of cellular protein catabolic process | 57/3467 | 155/18723 | 6.01e-08 | 3.15e-06 | 57 |
GO:00066052 | Colorectum | MSS | protein targeting | 97/3467 | 314/18723 | 6.76e-08 | 3.46e-06 | 97 |
GO:00331572 | Colorectum | MSS | regulation of intracellular protein transport | 76/3467 | 229/18723 | 7.03e-08 | 3.56e-06 | 76 |
GO:00323862 | Colorectum | MSS | regulation of intracellular transport | 102/3467 | 337/18723 | 9.73e-08 | 4.71e-06 | 102 |
GO:00108212 | Colorectum | MSS | regulation of mitochondrion organization | 53/3467 | 144/18723 | 1.67e-07 | 7.55e-06 | 53 |
GO:00313962 | Colorectum | MSS | regulation of protein ubiquitination | 70/3467 | 210/18723 | 1.88e-07 | 8.26e-06 | 70 |
GO:00301112 | Colorectum | MSS | regulation of Wnt signaling pathway | 98/3467 | 328/18723 | 3.37e-07 | 1.36e-05 | 98 |
GO:00705852 | Colorectum | MSS | protein localization to mitochondrion | 47/3467 | 125/18723 | 3.98e-07 | 1.58e-05 | 47 |
GO:00105062 | Colorectum | MSS | regulation of autophagy | 95/3467 | 317/18723 | 4.36e-07 | 1.71e-05 | 95 |
GO:00324342 | Colorectum | MSS | regulation of proteasomal ubiquitin-dependent protein catabolic process | 49/3467 | 134/18723 | 6.02e-07 | 2.26e-05 | 49 |
GO:00160552 | Colorectum | MSS | Wnt signaling pathway | 124/3467 | 444/18723 | 6.06e-07 | 2.26e-05 | 124 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GSK3A | SNV | Missense_Mutation | | c.430N>G | p.Leu144Val | p.L144V | P49840 | protein_coding | tolerated(0.34) | benign(0.005) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
GSK3A | SNV | Missense_Mutation | rs750207489 | c.757N>A | p.Asp253Asn | p.D253N | P49840 | protein_coding | tolerated(0.54) | benign(0.286) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
GSK3A | SNV | Missense_Mutation | | c.710N>T | p.Ser237Phe | p.S237F | P49840 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
GSK3A | SNV | Missense_Mutation | | c.758N>G | p.Asp253Gly | p.D253G | P49840 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD |
GSK3A | insertion | Frame_Shift_Ins | novel | c.1322_1323insTACAGGCGTGAAC | p.Pro442ThrfsTer26 | p.P442Tfs*26 | P49840 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
GSK3A | insertion | Frame_Shift_Ins | novel | c.1320_1321insCCGCTTGGCCTCCTAAAGTGTTGGG | p.Ile441ProfsTer31 | p.I441Pfs*31 | P49840 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
GSK3A | SNV | Missense_Mutation | novel | c.787N>A | p.Asp263Asn | p.D263N | P49840 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSK3A | SNV | Missense_Mutation | novel | c.616G>C | p.Ala206Pro | p.A206P | P49840 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
GSK3A | SNV | Missense_Mutation | novel | c.288C>A | p.Asp96Glu | p.D96E | P49840 | protein_coding | tolerated(0.21) | benign(0.056) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
GSK3A | SNV | Missense_Mutation | | c.1264N>G | p.Leu422Val | p.L422V | P49840 | protein_coding | deleterious(0) | benign(0.377) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | Thiadiazolidindione derivative 2 | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | PMID27828716-Compound-BIO-acetoxime | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | CHIR-99021 | CHIR-99021 | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | inhibitor | 249565696 | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | PHA-767491 | CHEMBL225519 | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | AR-A014418 | CHEMBL259850 | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | KENPAULLONE | KENPAULLONE | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | PMID27828716-Compound-17 | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | Maleimides derivative 3 | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | Indazole derivative 6 | | |